Henry Schein (NASDAQ:HSIC) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of Henry Schein (NASDAQ:HSIC) from a buy rating to a hold rating in a research report released on Saturday.

HSIC has been the topic of several other research reports. Barrington Research reaffirmed an “outperform” rating and issued a $78.00 price target on shares of Henry Schein in a report on Tuesday, September 23rd. UBS Group lowered their price target on Henry Schein from $75.00 to $70.00 and set a “neutral” rating on the stock in a report on Wednesday, August 6th. Leerink Partners set a $75.00 price target on Henry Schein in a report on Monday, July 14th. Evercore ISI raised Henry Schein from an “in-line” rating to an “outperform” rating and set a $83.00 price target on the stock in a report on Tuesday, August 26th. Finally, JPMorgan Chase & Co. lowered their price target on Henry Schein from $80.00 to $76.00 and set an “overweight” rating on the stock in a report on Thursday, August 7th. Five analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, Henry Schein currently has a consensus rating of “Hold” and a consensus target price of $76.67.

Henry Schein Stock Performance

Shares of HSIC opened at $63.00 on Friday. The stock’s 50-day simple moving average is $67.34 and its 200 day simple moving average is $68.76. The stock has a market capitalization of $7.64 billion, a price-to-earnings ratio of 20.32, a price-to-earnings-growth ratio of 2.08 and a beta of 0.81. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.78 and a current ratio of 1.41. Henry Schein has a 52-week low of $60.56 and a 52-week high of $82.49.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.10 earnings per share for the quarter, missing the consensus estimate of $1.19 by ($0.09). Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The business had revenue of $3.24 billion during the quarter, compared to analysts’ expectations of $3.22 billion. During the same period in the previous year, the business earned $1.23 EPS. The business’s revenue was up 3.3% on a year-over-year basis. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. Research analysts forecast that Henry Schein will post 4.74 EPS for the current fiscal year.

Hedge Funds Weigh In On Henry Schein

Institutional investors and hedge funds have recently bought and sold shares of the stock. CYBER HORNET ETFs LLC bought a new position in Henry Schein during the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc bought a new position in Henry Schein during the 2nd quarter worth approximately $27,000. Rakuten Securities Inc. bought a new position in Henry Schein during the 1st quarter worth approximately $34,000. ANTIPODES PARTNERS Ltd bought a new position in Henry Schein during the 2nd quarter worth approximately $43,000. Finally, Steph & Co. bought a new position in Henry Schein during the 2nd quarter worth approximately $44,000. 96.62% of the stock is currently owned by institutional investors.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.